The global allergy diagnostics and therapeutics market size is calculated at USD 38.76 billion in 2025 and is forecasted to reach around USD 70.77 billion by 2034, accelerating at a CAGR of 6.93% from 2025 to 2034. The North America allergy diagnostics and therapeutics market size surpassed USD 13.40 billion in 2024 and is expanding at a CAGR of 6.95% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Allergy Diagnostics and Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Allergy Diagnostics and Therapeutics Market, by Product
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast
8.1.3. Services
8.1.3.1. Market Revenue and Forecast
9.1. Allergy Diagnostics and Therapeutics Market, by Drug Class
9.1.1. Nasal Anti-cholinergic
9.1.1.1. Market Revenue and Forecast
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast
9.1.3. Corticosteroids
9.1.3.1. Market Revenue and Forecast
9.1.4. Mast Cell Stabilizers
9.1.4.1. Market Revenue and Forecast
9.1.5. Leukotriene Inhibitors
9.1.5.1. Market Revenue and Forecast
9.1.6. Epinephrine
9.1.6.1. Market Revenue and Forecast
9.1.7. Immunotherapy
9.1.7.1. Market Revenue and Forecast
9.1.8. Decongestants
9.1.8.1. Market Revenue and Forecast
9.1.9. Immuno-modulators
9.1.9.1. Market Revenue and Forecast
10.1. Allergy Diagnostics and Therapeutics Market, by March
10.1.1. In vivo Test
10.1.1.1. Market Revenue and Forecast
10.1.2. In vitro Test
10.1.2.1. Market Revenue and Forecast
11.1. Allergy Diagnostics and Therapeutics Market, by By Allergen Type
11.1.1. Food
11.1.1.1. Market Revenue and Forecast
11.1.2. Inhaled
11.1.2.1. Market Revenue and Forecast
11.1.3. Drug
11.1.3.1. Market Revenue and Forecast
11.1.4. Other Allergens
11.1.4.1. Market Revenue and Forecast
12.1. Allergy Diagnostics and Therapeutics Market, by End-user
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Diagnostics Labs
12.1.2.1. Market Revenue and Forecast
12.1.3. Research & Development Centers
12.1.3.1. Market Revenue and Forecast
12.1.4. Others
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product
13.1.2. Market Revenue and Forecast, by Drug Class
13.1.3. Market Revenue and Forecast, by Test
13.1.4. Market Revenue and Forecast, by By Allergen Type
13.1.5. Market Revenue and Forecast, by End-user
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product
13.1.6.2. Market Revenue and Forecast, by Drug Class
13.1.6.3. Market Revenue and Forecast, by Test
13.1.6.4. Market Revenue and Forecast, by By Allergen Type
13.1.6.5. Market Revenue and Forecast, by End-user
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product
13.1.7.2. Market Revenue and Forecast, by Drug Class
13.1.7.3. Market Revenue and Forecast, by Test
13.1.7.4. Market Revenue and Forecast, by By Allergen Type
13.1.7.5. Market Revenue and Forecast, by End-user
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product
13.2.2. Market Revenue and Forecast, by Drug Class
13.2.3. Market Revenue and Forecast, by Test
13.2.4. Market Revenue and Forecast, by By Allergen Type
13.2.5. Market Revenue and Forecast, by End-user
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product
13.2.6.2. Market Revenue and Forecast, by Drug Class
13.2.6.3. Market Revenue and Forecast, by Test
13.2.7. Market Revenue and Forecast, by By Allergen Type
13.2.8. Market Revenue and Forecast, by End-user
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product
13.2.9.2. Market Revenue and Forecast, by Drug Class
13.2.9.3. Market Revenue and Forecast, by Test
13.2.10. Market Revenue and Forecast, by By Allergen Type
13.2.11. Market Revenue and Forecast, by End-user
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product
13.2.12.2. Market Revenue and Forecast, by Drug Class
13.2.12.3. Market Revenue and Forecast, by Test
13.2.12.4. Market Revenue and Forecast, by By Allergen Type
13.2.13. Market Revenue and Forecast, by End-user
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product
13.2.14.2. Market Revenue and Forecast, by Drug Class
13.2.14.3. Market Revenue and Forecast, by Test
13.2.14.4. Market Revenue and Forecast, by By Allergen Type
13.2.15. Market Revenue and Forecast, by End-user
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product
13.3.2. Market Revenue and Forecast, by Drug Class
13.3.3. Market Revenue and Forecast, by Test
13.3.4. Market Revenue and Forecast, by By Allergen Type
13.3.5. Market Revenue and Forecast, by End-user
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product
13.3.6.2. Market Revenue and Forecast, by Drug Class
13.3.6.3. Market Revenue and Forecast, by Test
13.3.6.4. Market Revenue and Forecast, by By Allergen Type
13.3.7. Market Revenue and Forecast, by End-user
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product
13.3.8.2. Market Revenue and Forecast, by Drug Class
13.3.8.3. Market Revenue and Forecast, by Test
13.3.8.4. Market Revenue and Forecast, by By Allergen Type
13.3.9. Market Revenue and Forecast, by End-user
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product
13.3.10.2. Market Revenue and Forecast, by Drug Class
13.3.10.3. Market Revenue and Forecast, by Test
13.3.10.4. Market Revenue and Forecast, by By Allergen Type
13.3.10.5. Market Revenue and Forecast, by End-user
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product
13.3.11.2. Market Revenue and Forecast, by Drug Class
13.3.11.3. Market Revenue and Forecast, by Test
13.3.11.4. Market Revenue and Forecast, by By Allergen Type
13.3.11.5. Market Revenue and Forecast, by End-user
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product
13.4.2. Market Revenue and Forecast, by Drug Class
13.4.3. Market Revenue and Forecast, by Test
13.4.4. Market Revenue and Forecast, by By Allergen Type
13.4.5. Market Revenue and Forecast, by End-user
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product
13.4.6.2. Market Revenue and Forecast, by Drug Class
13.4.6.3. Market Revenue and Forecast, by Test
13.4.6.4. Market Revenue and Forecast, by By Allergen Type
13.4.7. Market Revenue and Forecast, by End-user
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product
13.4.8.2. Market Revenue and Forecast, by Drug Class
13.4.8.3. Market Revenue and Forecast, by Test
13.4.8.4. Market Revenue and Forecast, by By Allergen Type
13.4.9. Market Revenue and Forecast, by End-user
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product
13.4.10.2. Market Revenue and Forecast, by Drug Class
13.4.10.3. Market Revenue and Forecast, by Test
13.4.10.4. Market Revenue and Forecast, by By Allergen Type
13.4.10.5. Market Revenue and Forecast, by End-user
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product
13.4.11.2. Market Revenue and Forecast, by Drug Class
13.4.11.3. Market Revenue and Forecast, by Test
13.4.11.4. Market Revenue and Forecast, by By Allergen Type
13.4.11.5. Market Revenue and Forecast, by End-user
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product
13.5.2. Market Revenue and Forecast, by Drug Class
13.5.3. Market Revenue and Forecast, by Test
13.5.4. Market Revenue and Forecast, by By Allergen Type
13.5.5. Market Revenue and Forecast, by End-user
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product
13.5.6.2. Market Revenue and Forecast, by Drug Class
13.5.6.3. Market Revenue and Forecast, by Test
13.5.6.4. Market Revenue and Forecast, by By Allergen Type
13.5.7. Market Revenue and Forecast, by End-user
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product
13.5.8.2. Market Revenue and Forecast, by Drug Class
13.5.8.3. Market Revenue and Forecast, by Test
13.5.8.4. Market Revenue and Forecast, by By Allergen Type
13.5.8.5. Market Revenue and Forecast, by End-user
14.1. R-Biopharm AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. EUROIMMUN Medizinische Labordiagnostika AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. DASIT Group SPA
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. bioMérieux
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Stallergenes Greer
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sun Pharmaceutical Industries Ltd
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Minaris Medical America, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Siemens Healthcare GmbH
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AESKU.GROUP GmbH
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample